{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:45:08Z","timestamp":1793213108790,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Pharmacyclics LLC, an AbbVie Company"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.leukres.2020.106432","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T11:35:15Z","timestamp":1597145715000},"page":"106432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"97","author":[{"given":"Isabelle G.","family":"Solman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana Y.","family":"Hoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline C.","family":"Barrientos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil E.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hillmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indu D.","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Mongan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.leukres.2020.106432_bib0005","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl 5","key":"10.1016\/j.leukres.2020.106432_bib0010","doi-asserted-by":"crossref","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","article-title":"Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Eichhorst","year":"2015","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2020.106432_bib0015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/j.seminhematol.2014.05.006","article-title":"Immunomodulation and immune reconstitution in chronic lymphocytic leukemia","volume":"51","author":"Riches","year":"2014","journal-title":"Semin. Hematol."},{"issue":"5","key":"10.1016\/j.leukres.2020.106432_bib0020","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2020.106432_bib0025","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2020.106432_bib0030","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood-2013-12-546416","article-title":"CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs","volume":"124","author":"Jitschin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106432_bib0035","series-title":"Presented at: 60th American Society of Hematology Annual Meeting","article-title":"Up to 7 years of follow-up of single-agent ibrutinib in the phase 1b\/2 PCYC-1102 trial of first line and relapsed\/refractory patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","author":"Byrd","year":"2018"},{"issue":"5","key":"10.1016\/j.leukres.2020.106432_bib0040","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/1078-0432.CCR-16-1431","article-title":"Extended treatment with single-agent ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"23","author":"Coutre","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2020.106432_bib0045","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","author":"Burger","year":"2019","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2020.106432_bib0050","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to 6 years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2020.106432_bib0055","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol."},{"issue":"26","key":"10.1016\/j.leukres.2020.106432_bib0060","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.leukres.2020.106432_bib0065","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.leukres.2020.106432_bib0070","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41375-018-0276-9","article-title":"Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"33","author":"Fraser","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.leukres.2020.106432_bib0075","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"19","key":"10.1016\/j.leukres.2020.106432_bib0080","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.leukres.2020.106432_bib0085","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2020.106432_bib0090","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-15-1965","article-title":"Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib--findings from an investigator-initiated phase II study","volume":"22","author":"Niemann","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.leukres.2020.106432_bib0095","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.4049\/jimmunol.1601190","article-title":"Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia","volume":"198","author":"Yin","year":"2017","journal-title":"J. Immunol."},{"issue":"23","key":"10.1016\/j.leukres.2020.106432_bib0100","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/blood.V126.23.1737.1737","article-title":"Ibrutinib can modulate the T cell response in chronic lymphocytic leukemia by reducing PD1\/PDL1 interactions","volume":"126","author":"Kondo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106432_bib0105","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.3389\/fimmu.2019.02832","article-title":"Long-term ibrutinib therapy reverses CD8(+) T cell exhaustion in B cell chronic lymphocytic leukaemia","volume":"10","author":"Parry","year":"2019","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.leukres.2020.106432_bib0110","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1158\/1078-0432.CCR-15-3106","article-title":"Arresting the inflammatory drive of chronic lymphocytic leukemia with ibrutinib","volume":"22","author":"Bachireddy","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.leukres.2020.106432_bib0115","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.leukres.2020.106432_bib0120","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.leukres.2020.106432_bib0125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.0902-4441.2003.00199.x","article-title":"Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland","volume":"72","author":"Bisset","year":"2004","journal-title":"Eur. J. Haematol."},{"issue":"12","key":"10.1016\/j.leukres.2020.106432_bib0130","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2020.106432_bib0135","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2013-09-527853","article-title":"Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2020.106432_bib0140","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/leu.2014.122","article-title":"Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study","volume":"28","author":"Herman","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2020.106432_bib0145","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1080\/10428194.2018.1512710","article-title":"Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib","volume":"60","author":"Barrientos","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2020.106432_bib0150","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3389\/fimmu.2017.01178","article-title":"Natural killer T cells in cancer immunotherapy","volume":"8","author":"Nair","year":"2017","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.leukres.2020.106432_bib0155","first-page":"379","article-title":"Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer","volume":"4","author":"Quatromoni","year":"2012","journal-title":"Am. J. Transl. Res."},{"issue":"1","key":"10.1016\/j.leukres.2020.106432_bib0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2050-7771-2-1","article-title":"Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases","volume":"2","author":"Yang","year":"2014","journal-title":"Biomark. Res."},{"issue":"2","key":"10.1016\/j.leukres.2020.106432_bib0165","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00262-005-0675-4","article-title":"T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil","volume":"55","author":"Mellstedt","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.leukres.2020.106432_bib0170","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/eji.201343751","article-title":"The who\u2019s who of T-cell differentiation: human memory T-cell subsets","volume":"43","author":"Mahnke","year":"2013","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.leukres.2020.106432_bib0175","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/sj.jid.5700001","article-title":"Cytotoxic T cells","volume":"126","author":"Andersen","year":"2006","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.leukres.2020.106432_bib0180","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3324\/haematol.2016.151100","article-title":"T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers","volume":"102","author":"Palma","year":"2017","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.leukres.2020.106432_bib0185","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/ejh.12880","article-title":"Frequency and functional characterization of exhausted CD8(+) T cells in chronic lymphocytic leukemia","volume":"98","author":"Taghiloo","year":"2017","journal-title":"Eur. J. Haematol."},{"issue":"3","key":"10.1016\/j.leukres.2020.106432_bib0190","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00580-014-1961-3","article-title":"Regulatory T cells in chronic lymphocytic leukemia","volume":"24","author":"Aref","year":"2014","journal-title":"Compar. Clin. Pathol."},{"issue":"12","key":"10.1016\/j.leukres.2020.106432_bib0195","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.clml.2018.08.007","article-title":"Improvement in parameters of hematologic and immunologic function and patient well-being in the phase III RESONATE study of ibrutinib versus ofatumumab in patients with previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"18","author":"Barrientos","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"7637","key":"10.1016\/j.leukres.2020.106432_bib0200","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.leukres.2020.106432_bib0205","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4049\/jimmunol.164.3.1322","article-title":"Annexin V binds to viable B cells and colocalizes with a marker of lipid rafts upon B cell receptor activation","volume":"164","author":"Dillon","year":"2000","journal-title":"J. Immunol."},{"issue":"13","key":"10.1016\/j.leukres.2020.106432_bib0210","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2006-03-011742","article-title":"Antigen recognition induces phosphatidylserine exposure on the cell surface of human CD8+ T cells","volume":"108","author":"Fischer","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2020.106432_bib0215","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/leu.2015.316","article-title":"BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia","volume":"30","author":"Chen","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2020.106432_bib0220","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"45","key":"10.1016\/j.leukres.2020.106432_bib0225","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1038\/onc.2008.271","article-title":"The tumor microenvironment and its role in promoting tumor growth","volume":"27","author":"Whiteside","year":"2008","journal-title":"Oncogene"},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2020.106432_bib0230","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2018-99-118333","volume":"132","author":"Papazoglou","year":"2018","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.leukres.2020.106432_bib0235","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood-2017-12-822569","article-title":"Improving CLL Vgamma9Vdelta2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib","volume":"132","author":"de Weerdt","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2020.106432_bib0240","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2018-99-111061","article-title":"Comparison of efficacy and toxicity of CD19-specific chimeric antigen receptor T-cells alone or in combination with ibrutinib for relapsed and\/or refractory CLL","volume":"132","author":"Gauthier","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2020.106432_bib0245","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620301375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620301375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:00:55Z","timestamp":1758934855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212620301375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":49,"alternative-id":["S0145212620301375"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106432","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106432"}}